RELATED CONTENT
NEWS
- CREW: Sanofi subpoena aims to muzzle watchdog, unmask whistleblower
- Paying $3B: GSK tops US criminal, civil settlements for off-label, other schemes
- SCOTUS rejects Amgen’s materiality proof before certification as cart before horse
- SCOTUS mulls limiting class actions in Amgen case

